chufangao/CTO huggingface dataset:
Clinical trial NCT03684642: Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Official title: A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Acronym: AMPLITUDE-D
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision to cancel TRIAL, not related to safety concern.
Enrollment: 908.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-26
Primary completion date: 2020-10-13
Completion date: 2020-11-17
Baseline population: Analysis was performed on intent-to-treat (ITT) population, which included all randomized participants, analyzed according to the treatment group allocated by randomization.
Limitations and caveats: The study was terminated early by the Sponsor on 09 September 2020. Due to early termination of the study, model-based efficacy analyses were performed in the mITT population instead of the ITT population originally planned and data was carefully considered given that the study was terminated early.
Plan to share individual participant data: NO
IPD sharing description: No plan to share individual participant data (IPD) by SANOFI: Product rights transferred to Hanmi Pharmaceutical.
Clinical trial NCT04005144: Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Official title: A Phase I Study of Brigatinib With Binimetinib in Advanced ALK- or ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low Accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-25
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Plan to share individual participant data: NO
Clinical trial NCT03877224: DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
Official title: International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 504.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-04
Primary completion date: 2020-07-09
Completion date: 2020-07-09
Baseline population: Full Analysis Set: All participants that were randomized, regardless of whether treated or not.
Limitations and caveats: In this study, a subset of participants received wearable activity monitors to wear at home for 3 periods of 7 days. Data collection from the wearable device was challenging and a substantial amount of data was missing. This limits the use of the data based on the wearable activity monitors to investigate the potential impact of study drug on the amount, duration, and intensity of physical activity.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.~All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03163459: Short-duration Selective Brain Cooling for Patients Undergoing Mechanical Thrombectomy
Official title: Short-duration Selective Brain Cooling for Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: a Randomized Controlled Trial
Sponsor: Capital Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: SUSPENDED 
Why stopped: Interim analysis
Enrollment: 120.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2018-02-06
Primary completion date: 2020-09-30
Completion date: 2020-12-16
Plan to share individual participant data: NO
Clinical trial NCT03697564: Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
Official title: Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
Sponsor: University of California, San Diego (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Working on getting accurate information for patients interested in the study.
Enrollment: 40.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2019-10-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Clinical trial NCT03417921: A Study of ABTL0812 in Pancreatic Cancer
Official title: A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy
Acronym: Pancreatic
Sponsor: Ability Pharmaceuticals SL (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: We opened another study.
Enrollment: 60.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2021-04-26
Primary completion date: 2023-04-26
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT02672358: Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
Official title: A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Company Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-03
Primary completion date: 2019-09-02
Completion date: 2020-12-07
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03992443: Efficacy and Safety of CUSA-081 in the Restoration of Dysfunctional Central Venous Access Device (CVAD) Functionality
Official title: A Phase 3, Open Label, Single Arm Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
Acronym: READY 2
Sponsor: Chiesi Farmaceutici S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Chiesi business decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-28
Primary completion date: 2022-03-18
Completion date: 2022-03-18
Plan to share individual participant data: NO
Clinical trial NCT04908475: Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Official title: A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 352.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-09
Primary completion date: 2023-04-20
Completion date: 2023-04-20
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT01593254: Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Official title: An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib
Acronym: DASCERN
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 262.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-09-12
Primary completion date: 2017-11-08
Completion date: 2022-04-12
Baseline population: All Randomized participants
Clinical trial NCT04333225: Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
Official title: A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures
Sponsor: Baylor Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 221.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-03
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Limitations and caveats: * Due to the off-label use of HCQ, we were not able to incorporate randomization in our design.~* The outcome of CLI was based on self-reported symptoms, which is prone to bias.~* The trial may be under-powered as recruitment was forced to stop early at 221 instead of 360 because of the demand for and subsequent shortage of HCQ in March 2020.~* Our study participants were young and healthy compared to other prophylaxis trials, which may partially explain the low rates of COVID-19.
Plan to share individual participant data: NO
Clinical trial NCT04616105: Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Volunteers
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 19.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-11-18
Primary completion date: 2021-05-28
Completion date: 2021-05-28
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Clinical trial NCT02675842: Investigation of Cannabis for Pain and Inflammation in Lung Cancer
Official title: Investigation of Cannabis for Pain and Inflammation in Lung Cancer
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Primary completion date: 2021-10-28
Completion date: 2021-10-28
Plan to share individual participant data: NO
Clinical trial NCT04135352: A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
Official title: A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Reasons
Enrollment: 35.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-11-04
Primary completion date: 2022-08-24
Completion date: 2022-08-24
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03246919: Ideal Time of Oxytocin Infusion During Cesarean Section
Official title: Ideal Time of Oxytocin Infusion During Cesarean Section
Acronym: I-TOPICS
Sponsor: Loyola University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: PI left Loyola and Sub-I graduated.
Enrollment: 68.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-13
Primary completion date: 2020-02-24
Completion date: 2020-02-24
Plan to share individual participant data: NO
Clinical trial NCT05156645: A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
Official title: An Adaptive Phase I/II/III Trial to Evaluate the Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibody Combination (SCTA01C and SCTA01) for Treatment of Outpatients With COVID-19
Sponsor: Sinocelltech Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: The study was withdraw due to the fast spread of Omicron variant worldwide
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-15
Primary completion date: 2022-12-01
Completion date: 2022-12-01
Plan to share individual participant data: YES
Clinical trial NCT03182907: Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
Official title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)
Acronym: MODIFY III
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 148.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-27
Primary completion date: 2022-05-12
Completion date: 2022-05-12
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05220748: RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC
Official title: A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
Sponsor: Rakuten Medical, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Decision was made due to a strategic re-evaluation of pipelines; no patients were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-24
Primary completion date: 2023-01-30
Completion date: 2023-01-30
Plan to share individual participant data: NO
Clinical trial NCT03850535: A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Official title: A Phase Ib/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2.
Enrollment: 24.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-03-25
Primary completion date: 2020-09-10
Completion date: 2020-09-10
Baseline population: There was no expansion phase taken place.
Plan to share individual participant data: NO
IPD sharing description: Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).~For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03370185: Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Official title: A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)
Acronym: BRIO
Sponsor: SecuraBio (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Reassessing corporate priorities.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-12
Primary completion date: 2020-06-30
Completion date: 2021-03-31
Plan to share individual participant data: NO
Clinical trial NCT04056650: Assessing the Effectiveness of an N-of-1 Platform Using Study of Cognitive Enhancers
Official title: Data Driven Health Decisions in the Wild: A Platform for Actionable N-of-1 Studies
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-18
Primary completion date: 2020-12-22
Completion date: 2020-12-22
Plan to share individual participant data: YES
Clinical trial NCT02346617: Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
Official title: Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection in Allogeneic Hematopoietic Cell Transplant Recipients
Sponsor: Samsung Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Due to the KoreaFDA issue
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-01-01
Primary completion date: 2023-12-01
Completion date: 2024-12-01
Clinical trial NCT03088813: Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
Official title: RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Acronym: RESILIENT
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 491.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-04-25
Primary completion date: 2022-02-08
Completion date: 2023-07-27
Baseline population: Part 1: Safety population included all enrolled participants who were treated with at least 1 dose of irinotecan liposome injection. Part 2: Intent-to-Treat (ITT) population included all randomized participants.
Clinical trial NCT04720742: Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation
Official title: Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation (ITATI)
Acronym: ITATI
Sponsor: IrsiCaixa (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Due to the COVID-19 pandemic the financial sponsor of the trial suspended the study funding due to funding limitations and based on various considerations, including the uncertainties of conducting the study in the volatile scenario of this pandemic.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-28
Primary completion date: 2022-03-28
Completion date: 2022-03-28
Clinical trial NCT02174575: Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery
Official title: Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study
Sponsor: Tokyo Medical and Dental University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: I retired my post before enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-31
Primary completion date: 2023-05-31
Completion date: 2023-05-31